R ecenta dvancesi nt he management of oncologic care andthe challenges arisingp ursuant to change have been particularly interestingi nt he area of colorectal cancer (CRC).Good interfaces amongdifferentfacetsofcare( e.g.,medicalmanagement, pharmacy management, care management, case management, patientadvocacy) have become crucial. Discussion of this topici st imely, especiallyw itht he increaseds crutiny health care is currentlye xperiencingf rome mployerg roups, insurancecompanies,and Medicare andMe dicaid agencies.
An understanding of cancer, andespeciallyCRC,isajourney that travels many roads. Some of them navigate through gastrointestinal cancerc linicalt rials, cancerc linical trials, biologictherapy development, or treatmentguidelines. In addition, this "traveler" needst ol ooka treport s, reviews, andbookchapters.Av arietyo fs ources supportt he workt hatl eads to these tools, includingthe NationalInstitutesofHealth,and thenumerousC ooperative Oncology Groups across thenation, individual researchers andi nvestigators,a nd event he Centerf or Medicare &MedicaidServices. Theresult: w ehave abetterunderstanding of CRC'se pidemiology, tumorbehavior at thecellularl evel,and preferredt herapies than everb efore. More important, therapies aree merging( andb eing reflected in thec onstantly changing standard of care)thathave improved patientcareinmeasurable ways.T herapy-induced toxicities arel ess severe,a nd in many cases, patients can be treatedwithless intrusiveoraltherapies.
Managedcare'sc omplexitiesand challengesrelated to cancer therapyare extensive. Clinicians andadministratorsmustexamineq uality of lifef or patients,v alue associated with newa nd oftencostly therapies, andbudgetissues. Increasingly,werelyon informatics,r eporting, anddataanalysist oguide ourd ecisions. With regard to cancer, we need focusedanalyses, benchmarking activities,a nd financial impactm odelst hata re differentf rom many developed to deal with othera cute or chronicd isease. Andcancer'simpacthas necessitated unique clinical evaluations, formularydevelopment, andcontractefforts.Managed care pharmacistsn eedt ok nowa bout thes pecifict herapeutic interventions, utilization management programs,management reporting tools, andhealth services research that theirorganization will use to make decisionsthatbestbenefit theirmembers.
Three changese nsuret hatc ancert reatment will be am ore pressingi ssue.F irst,m anyn ewert herapies areb eing formulatedaso ralagents. This movesmedicationfromthe physician's office or clinic to communityo ro utpatientp harmaciesint erms of patienta ccess andp ayment. Second,m anyn ew agents are 
